Wall Street analysts expect Ophthotech Corp (NASDAQ:OPHT) to report earnings of ($0.37) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Ophthotech’s earnings. Ophthotech reported earnings of ($0.26) per share in the same quarter last year, which indicates a negative year over year growth rate of 42.3%. The business is expected to report its next quarterly earnings results on Tuesday, February 26th.
On average, analysts expect that Ophthotech will report full year earnings of ($1.55) per share for the current fiscal year, with EPS estimates ranging from ($1.59) to ($1.51). For the next fiscal year, analysts forecast that the company will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.40) to ($1.16). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Ophthotech.
Ophthotech (NASDAQ:OPHT) last issued its earnings results on Wednesday, October 31st. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.02.
Several equities research analysts have recently weighed in on OPHT shares. Zacks Investment Research cut shares of Ophthotech from a “hold” rating to a “sell” rating in a research report on Wednesday, November 28th. ValuEngine cut shares of Ophthotech from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 4th. Two analysts have rated the stock with a sell rating and two have given a hold rating to the company. The stock has an average rating of “Hold” and an average target price of $3.50.
Several institutional investors and hedge funds have recently made changes to their positions in OPHT. Bridgeway Capital Management Inc. lifted its position in shares of Ophthotech by 93.1% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 217,400 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 104,800 shares during the period. Spark Investment Management LLC lifted its position in Ophthotech by 25.1% during the second quarter. Spark Investment Management LLC now owns 536,300 shares of the biopharmaceutical company’s stock valued at $1,464,000 after acquiring an additional 107,600 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in Ophthotech by 80.6% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 739,987 shares of the biopharmaceutical company’s stock valued at $2,020,000 after acquiring an additional 330,226 shares during the last quarter. BlackRock Inc. lifted its position in Ophthotech by 30.2% during the second quarter. BlackRock Inc. now owns 775,458 shares of the biopharmaceutical company’s stock valued at $2,116,000 after acquiring an additional 179,924 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Ophthotech by 10.5% during the third quarter. Dimensional Fund Advisors LP now owns 958,137 shares of the biopharmaceutical company’s stock valued at $2,261,000 after acquiring an additional 91,041 shares during the last quarter. 47.02% of the stock is owned by hedge funds and other institutional investors.
Shares of OPHT stock opened at $1.64 on Friday. Ophthotech has a one year low of $1.62 and a one year high of $4.50. The stock has a market capitalization of $72.63 million, a price-to-earnings ratio of 0.52 and a beta of 1.16.
Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.